Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Rebecca Svanberg Teglgaard, Rudi Agius, Caspar da Cunha-Bang, Tereza Faitova, Christian Brieghel, Hans Jakob Hartling, Hanne Vibeke Marquart, Robert Schou Pedersen, Christian Bjørn Poulsen, Mark-David Levin, Fransien De Boer, Koen de Heer, Rikke Kragh Lauridsen, Joanne Reekie, Anders Österborg, Jeanette Lundin, Magdalena Kättström, Sisse Rye Ostrowski, Carsten Utoft Niemann

Blood (2024) 144 (Supplement 1): 4609.

https://doi.org/10.1182/blood-2024-204985

Published: 2024

Journal Articles

Cellular and Molecular Effects of Suspending Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia in Sustained Partial Remission

Marzia Palma, Maria Lisa Andersson, Tom Adriaan Mulder, Kia Heimersson, Anna Berglöf, Lucia Peña Perez, Teresa Del Peso Santos, Yesid Alvarado Valero, Rula Zain-Luqman, Robert Månsson, Richard Rosenquist, Edvard C.I. Smith, Anders Österborg, Jeanette Lundin

Blood (2024) 144 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2024-198001

Published: 2024

Journal Articles

A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells

Mohammad Hojjat-Farsangi, Wen Zhong, Tom Mulder, Ann Svensson, Jeanette Lundin, Marzia Palma, Johan Schultz, Thomas Olin, Bjorn Wahlin, Anders Osterborg, Parviz Kokhaei, Hakan Mellstedt

Blood (2023) 142 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2023-185953

Published: 2023

Journal Articles

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Maria Winqvist, MSc, MD, Per-Ola Andersson, MD PhD, Anna Asklid, MD, Karin Karlsson, MD, Claes Karlsson, MD PhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD Assoc Prof, Mattias Mattsson, MD, Stefan Norin, MD PhD, Anna Bergendahl Sandstedt, MD, Lotta Hansson, Anders Österborg, MD PhD Prof.

Blood (2017) 130 (Supplement 1): 5353.

https://doi.org/10.1182/blood.V130.Suppl_1.5353.5353

Published: 2017

Journal Articles

Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Marzia Palma, MD PhD, Aleksandra Krstic, PhD, Anna Berglöf, PhD, Qing Wang, PhD, Emelie Blomberg, PhD, Stephan Meinke, PhD, Masood Kamali-Moghaddam, PhD, Qiujin Shen, PhD, Georg Jaremko, MD PhD, Jeanette Lundin, MD PhD, Eva Kimby, MD professor, Petter Höglund, MD PhD, Robert Månsson, PhD, Anders Österborg, MD PhD, Edvard Smith, PhD

Blood (2016) 128 (22): 3235.

https://doi.org/10.1182/blood.V128.22.3235.3235

Published: 2016

Journal Articles

A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update

Jeanette Lundin, MD PhD, Steven T. Rosen, MD, Anders Österborg, MDPhD, Olga Frankfurt, MD, Jane N. Winter, MD, Alfred Rademaker, Jennifer Kreutzer, Elizabeth Bacon, Sonja Sönnert-Husa, Shuo Ma, MD PhD

Blood (2015) 126 (23): 1734.

https://doi.org/10.1182/blood.V126.23.1734.1734

Published: 2015

Journal Articles

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Maria Winqvist, MD, Fariba Mozaffari, PhD, Marzia Palma, MD PhD, Sandra Eketorp Sylvan, MD PhD, Hakan Mellstedt, MD PhD, Anders Osterborg, MD PhD, Jeanette Lundin, MD PhD

Blood (2015) 126 (23): 4164.

https://doi.org/10.1182/blood.V126.23.4164.4164

Published: 2015

Journal Articles

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Lotta Hansson, MD PhD, Maria Winqvist, MD, Anna Asklid, MD, P-O Andersson, MDPhD, Karin Karlsson, MD, Claes Karlsson, MDPhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD, Mattias Mattsson, MD, Stefan Norin, MDPhD, Anna Sandstedt, MD, Anders Österborg, MDPhD

Blood (2015) 126 (23): 1745.

https://doi.org/10.1182/blood.V126.23.1745.1745

Published: 2015

Journal Articles

a Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Shuo Ma, MD PhD, Steven T. Rosen, MD, Olga Frankfurt, MD, Jane N. Winter, MD, Jennifer Kreutzer, Sonja Husa, Anders Österborg, Jeanette Lundin, MD

Blood (2014) 124 (21): 4686.

https://doi.org/10.1182/blood.V124.21.4686.4686

Published: 2014

Journal Articles

Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Mohammad R. Rezvany, Mahmood J. Tehrani, Claes Karlsson, Jeanette Lundin, Hodjattallah Rabbani, Håkan Mellstedt, Anders Österborg

Blood (2005) 106 (11): 2986.

https://doi.org/10.1182/blood.V106.11.2986.2986

Published: 2005

Journal Articles

Treatment of Refractory Autoimmune Hemolytic Anemia in B-CLL with Alemtuzumab (Humanized CD52 MAb).

Jeanette Lundin, F. Celsing, C. Karlsson, A. Osterborg

Blood (2005) 106 (11): 2967.

https://doi.org/10.1182/blood.V106.11.2967.2967

Published: 2005

Journal Articles

No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome

Jeanette Lundin, Ben Kennedy, Claire Dearden, Martin J. S. Dyer, Anders Österborg

Blood (2005) 105 (10): 4148–4149.

https://doi.org/10.1182/blood-2004-11-4314

Published: 2005

Journal Articles

T-Cell Function in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Following Alemtuzumab (Campath®) or Fludarabine Treatment.

Shahryar Kiaii, Fariba Mozaffari, Jeanette Lundin, Reza Rezvany, Aniruddha Chudhury, Håkan Mellstedt, Anders Osterborg

Blood (2004) 104 (11): 2513.

https://doi.org/10.1182/blood.V104.11.2513.2513

Published: 2004

Journal Articles

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

Geoff Hale, Peppy Rebello, Lee R. Brettman, Chris Fegan, Ben Kennedy, Eva Kimby, Mike Leach, Jeanette Lundin, Håkan Mellstedt, Paul Moreton, Andy C. Rawstron, Herman Waldmann, Anders Osterborg, Peter Hillmen

Blood (2004) 104 (4): 948–955.

https://doi.org/10.1182/blood-2004-02-0593

Published: 2004

Journal Articles

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Gunilla Enblad, Hans Hagberg, Martin Erlanson, Jeanette Lundin, Anja Porwit MacDonald, Roland Repp, Johannes Schetelig, Gernot Seipelt, Anders Österborg

Blood (2004) 103 (8): 2920–2924.

https://doi.org/10.1182/blood-2003-10-3389

Published: 2004

Journal Articles

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome

Jeanette Lundin, Hans Hagberg, Roland Repp, Eva Cavallin-Ståhl, Susanne Fredén, Gunnar Juliusson, Eija Rosenblad, Geir Tjønnfjord, Tom Wiklund, Anders Österborg

Blood (2003) 101 (11): 4267–4272.

https://doi.org/10.1182/blood-2002-09-2802

Published: 2003

Journal Articles

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Jeanette Lundin, Eva Kimby, Magnus Björkholm, Per-Anders Broliden, Fredrik Celsing, Viktoria Hjalmar, Lars Möllgård, Peppy Rebello, Geoff Hale, Herman Waldmann, Håkan Mellstedt, Anders Österborg

Blood (2002) 100 (3): 768–773.

https://doi.org/10.1182/blood-2002-01-0159

Published: 2002

NARROW

Improved Innate Immune Function upon Preemptive Short-Term Acalabrutinib and Venetoclax in Newly Diagnosed CLL Patients with High Risk of Infections: Translational Findings from the Prevent-Acall Clinical Trial

Cellular and Molecular Effects of Suspending Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia in Sustained Partial Remission

A CX3CR1 (fractalkine receptor) Small Molecular Antagonist (KAND567) Suppressed the Growth Promoting Effect of Monocytes on Chronic Lymphocytic Leukemia Cells

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

a Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Reconstitution of the T Cell Repertoire Following Treatment with Alemtuzumab in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL).

Treatment of Refractory Autoimmune Hemolytic Anemia in B-CLL with Alemtuzumab (Humanized CD52 MAb).

No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome

T-Cell Function in Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL) Following Alemtuzumab (Campath®) or Fludarabine Treatment.

Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration

A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas

Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sézary syndrome

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only